

AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA) Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083 Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Ref: Akums/Exchange/2024-25/30

November 9, 2024

To, The Listing Department National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E),Mumbai – 400 051 To, The Listing Department BSE Limited Rotunda Building, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001

Symbol: AKUMS

Scrip Code: 544222

Sub: Statement for deviation(s) or variation(s) for the quarter ended 30th September, 2024.

Respected Sir/Madam,

Pursuant to Regulation 32(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith the Statement of deviation(s) or variation(s) of funds raised through Initial Public Offer for the quarter ended September 30, 2024. Further, we hereby confirm that there is no deviation or variation in utilization of proceeds raised through Initial Public Offer.

The statement has been reviewed and approved by the Audit Committee in its meeting held today i.e. November 9, 2024.

This is for your kind information and record.

Thanking You

For Akums Drugs and Pharmaceuticals Limited

Dharamvir Malik Company Secretary & Compliance Officer



ISO 9001 : 2015 ISO 14001 : 2015 ISO 17025 : 2005 (NABL)






AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA) Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083 Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Name of listed entity	Akums Drugs and Pharmaceuticals Limited					
Mode of Fund Raising	Public Issues					
Date of Raising Funds	August 2, 2024 (Listed on August 6, 2024 on BSE Limited and National Stock Exchange of India Limited)					
Amount Raised	6800.00 million					
Report filed for Quarter ended	30-09-2024					
Monitoring Agency	Applicable					
Monitoring Agency Name, if applicable	CRISIL Ratings Limited					
Is there a Deviation / Variation in use of funds raised	No					
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable					
If Yes, Date of shareholder Approval	Not Applicable					
Explanation for the Deviation / Variation	Not Applicable					
Comments of the Audit Committee after review	No Comments					
Comments of the auditors, if any	No Comments					
Objects for which funds have been ra	ised and whe	ere there has	been a dev	iation, in th)
Original Object	Modified Object, if any	Original Allocatio n	Modified allocatio n, if any	Funds Utilised	Amount of Deviation/Vari ation for the quarter according to applicable object	Remark s if any
Repayment/ prepayment of indebtedness of the Company	Not Applicable	1,599.10	0	1,599.10	0	-
Repayment/ prepayment of indebtedness of its Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited	Not Applicable	2,270.90	0	0	0	-
Funding incremental working capital requirements of our Company	Not Applicable	550.00	0	0	0	-
Pursuing inorganic growth initiatives through acquisitions	Not Applicable	278.70	0	0	0	-
General corporate purposes (GCP)*	Not Applicable	1,675.00	0	619.93	0	-
Total		6,373.70**		2,219.03	٨	0



ISO 9001 : 2015 ISO 14001 : 2015 ISO 17025 : 2005 (NABL) WHO-GMP US : NSF H A C C P





AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA) Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083 Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

*The amount utilized for general corporate purposes does not exceed 25% of the Gross Proceeds (amounting to Rs 1700.00 million) from the Fresh Issue.

** The amount of original allocation represents the amount raised through fresh Issue net of offer expenses as mentioned in the prospectus dated August 1, 2024.

Deviation or variation could mean:


(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Charles in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc

Sumeet Sood Chief Financial Officer Date: 07.11.2024

Place: Delhi



ISO 9001 : 2015 ISO 14001 : 2015 ISO 17025 : 2005 (NABL)

WHO-GMP US : NSF H A C C P

